Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders

Bibliography

• Di Marzo V, Bisogno T, De Petrocellis L. Endocannabinoids and related compounds: walking back and forth between plant natural products and animal physiology. Chem Biol 2007;14(7):741-56
   PubMed Web of Science ®Google Scholar
• Ahn K, McKinney MK, Cravatt BF. Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chem Rev 2008;108(5):1687-707
   PubMed Web of Science ®Google Scholar
• Fowler CJ. The cannabinoid system and its pharmacological manipulation--a review, with emphasis upon the uptake and hydrolysis of anandamide. Fundam Clin Pharmacol 2006;20(6):549-62
   PubMed Web of Science ®Google Scholar
• Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006;58(3):389-462
   PubMed Web of Science ®Google Scholar
• Cravatt BF, Giang DK, Mayfield SP, et al. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 1996;384(6604):83-7
   PubMed Web of Science ®Google Scholar
• McKinney MK, Cravatt BF. Structure and function of fatty acid amide hydrolase. Annu Rev Biochem 2005;74:411-32
   PubMed Web of Science ®Google Scholar
• Dinh TP, Freund TF, Piomelli D. A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation. Chem Phys Lipids 2002;121(1-2):149-58
   PubMed Web of Science ®Google Scholar
• Mackie K. Cannabinoid receptors as therapeutic targets. Annu Rev Pharmacol Toxicol 2006;46:101-22
   PubMed Web of Science ®Google Scholar
• Mechoulam R. Marihuana chemistry. Science 1970;168(936):1159-66
   PubMed Web of Science ®Google Scholar
• Lambert DM, Vandevoorde S, Jonsson KO, Fowler CJ. The palmitoylethanolamide family: a new class of anti-inflammatory agents? Curr Med Chem 2002;9:663-74
   PubMed Web of Science ®Google Scholar
• Cravatt BF, Demarest K, Patricelli MP, et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 2001;98(16):9371-6
   PubMed Web of Science ®Google Scholar
• Kathuria S, Gaetani S, Fegley D, et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 2003;9(1):76-81
   PubMed Web of Science ®Google Scholar
• Lichtman AH, Shelton CC, Advani T, Cravatt BF. Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia. Pain 2004;109(3):319-27
   PubMed Web of Science ®Google Scholar
• Chang L, Luo L, Palmer JA, et al. Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms. Br J Pharmacol 2006;148(1):102-13
   PubMed Web of Science ®Google Scholar
• Russo R, Loverme J, La Rana G, et al. The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3′-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice. J Pharmacol Exp Ther 2007;322(1):236-42
   PubMed Web of Science ®Google Scholar
• Cravatt BF, Saghatelian A, Hawkins EG, et al. Functional disassociation of the central and peripheral fatty acid amide signaling systems. Proc Natl Acad Sci USA 2004;101(29):10821-6
   PubMed Web of Science ®Google Scholar
• Massa F, Marsicano G, Hermann H, et al. The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest 2004;113(8):1202-9
   PubMed Web of Science ®Google Scholar
• Holt S, Comelli F, Costa B, Fowler CJ. Inhibitors of fatty acid amide hydrolase reduce carrageenan-induced hind paw inflammation in pentobarbital-treated mice: comparison with indomethacin and possible involvement of cannabinoid receptors. Br J Pharmacol 2005;146(3):467-76
   PubMed Web of Science ®Google Scholar
• Naidu PS, Varvel SA, Ahn K, et al. Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality. Psychopharmacology (Berl) 2007;192(1):61-70
   PubMed Web of Science ®Google Scholar
• Moreira FA, Kaiser N, Monory K, Lutz B. Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors. Neuropharmacology 2008;54(1):141-50
   PubMed Web of Science ®Google Scholar
• Gobbi G, Bambico FR, Mangieri R, et al. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci USA 2005;102(51):18620-5
   PubMed Web of Science ®Google Scholar
• Lichtman AH, Leung D, Shelton CC, et al. Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. J Pharmacol Exp Ther 2004;311(2):441-8
   PubMed Web of Science ®Google Scholar
• Boger DL, Sato H, Lerner AE, et al. Exceptionally potent inhibitors of fatty acid amide hydrolase: the enzyme responsible for degradation of endogenous oleamide and anandamide. Proc Natl Acad Sci USA 2000;97:5044-9
   PubMed Web of Science ®Google Scholar
• Cravatt BF, Lichtman AH. Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system. Curr Opin Chem Biol 2003;7(4):469-75
   PubMed Web of Science ®Google Scholar
• Lambert DM, Fowler CJ. The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. J Med Chem 2005;48(16):5059-87
   PubMed Web of Science ®Google Scholar
• Sugiura T, Kishimoto S, Oka S, Gokoh M. Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. Prog Lipid Res 2006;45(5):405-46
   PubMed Web of Science ®Google Scholar
• Okamoto Y, Wang J, Morishita J, Ueda N. Biosynthetic pathways of the endocannabinoid anandamide. Chem Biodivers 2007;4(8):1842-57
   PubMed Web of Science ®Google Scholar
• Seierstad M, Breitenbucher JG. Discovery and Development of Fatty Acid Amide Hydrolase (FAAH) Inhibitors. J Med Chem 2008;51(23):7327-43
   PubMed Web of Science ®Google Scholar
• Di Marzo V. Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov 2008;7(5):438-55
   PubMed Web of Science ®Google Scholar
• Basavarajappa BS. Critical enzymes involved in endocannabinoid metabolism. Protein Pept Lett 2007;14(3):237-46
   PubMed Web of Science ®Google Scholar
• Mileni M, Johnson DS, Wang Z, et al. Structure-guided inhibitor design for human FAAH by interspecies active site conversion. Proc Natl Acad Sci USA 2008;105(35):12820-4
   PubMed Web of Science ®Google Scholar
• Ahn K, Johnson DS, Mileni M, et al. Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chem Biol 2009;16(4):411-20
   PubMed Web of Science ®Google Scholar
• Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992;258(5090):1946-9
   PubMed Web of Science ®Google Scholar
• Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 2003;4(11):873-84
   PubMed Web of Science ®Google Scholar
• Hillard CJ, Jarrahian A. Cellular accumulation of anandamide: consensus and controversy. Br J Pharmacol 2003;140(5):802-8
   PubMed Web of Science ®Google Scholar
• Glaser ST, Kaczocha M, Deutsch DG. Anandamide transport: a critical review. Life Sci 2005;77(14):1584-604
   PubMed Web of Science ®Google Scholar
• Schmid PC, Zuzarte-Augustin ML, Schmid HH. Properties of rat liver N-acylethanolamine amidohydrolase. J Biol Chem 1985;260(26):14145-9
   PubMed Web of Science ®Google Scholar
• Deutsch DG, Chin SA. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem Pharmacol 1993;46(5):791-6
   PubMed Web of Science ®Google Scholar
• Desarnaud F, Cadas H, Piomelli D. Anandamide amidohydrolase activity in rat brain microsomes. Identification and partial characterization. J Biol Chem 1995;270(11):6030-5
   PubMed Web of Science ®Google Scholar
• Ueda N, Kurahashi Y, Yamamoto S, Tokunaga T. Partial purification and characterization of the porcine brain enzyme hydrolyzing and synthesizing anandamide. J Biol Chem 1995;270(40):23823-7
   PubMed Web of Science ®Google Scholar
• Hillard CJ, Wilkison DM, Edgemond WS, Campbell WB. Characterization of the kinetics and distribution of N-arachidonylethanolamine (anandamide) hydrolysis by rat brain. Biochim Biophys Acta 1995;1257(3):249-56
   PubMed Web of Science ®Google Scholar
• Cravatt BF, Prospero-Garcia O, Siuzdak G, et al. Chemical characterization of a family of brain lipids that induce sleep. Science 1995;268(5216):1506-9
   PubMed Web of Science ®Google Scholar
• Maurelli S, Bisogno T, De Petrocellis L, et al. Two novel classes of neuroactive fatty acid amides are substrates for mouse neuroblastoma ‘anandamide amidohydrolase’. FEBS Lett 1995;377(1):82-6
   PubMed Web of Science ®Google Scholar
• Giang DK, Cravatt BF. Molecular characterization of human and mouse fatty acid amide hydrolases. Proc Natl Acad Sci USA 1997;94(6):2238-42
   PubMed Web of Science ®Google Scholar
• Goparaju SK, Kurahashi Y, Suzuki H, et al. Anandamide amidohydrolase of porcine brain: cDNA cloning, functional expression and site-directed mutagenesis(1). Biochim Biophys Acta 1999;1441(1):77-84
   PubMed Web of Science ®Google Scholar
• Egertova M, Giang DK, Cravatt BF, Elphick MR. A new perspective on cannabinoid signalling: complementary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain. Proc Biol Sci 1998;265(1410):2081-5
   PubMed Web of Science ®Google Scholar
• Gulyas AI, Cravatt BF, Bracey MH, et al. Segregation of two endocannabinoid-hydrolyzing enzymes into pre- and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala. Eur J Neurosci 2004;20(2):441-58
   PubMed Web of Science ®Google Scholar
• Chebrou H, Bigey F, Arnaud A, Galzy P. Study of the amidase signature group. Biochim Biophys Acta 1996;1298(2):285-93
   PubMed Web of Science ®Google Scholar
• Patricelli MP, Lashuel HA, Giang DK, et al. Comparative characterization of a wild type and transmembrane domain-deleted fatty acid amide hydrolase: identification of the transmembrane domain as a site for oligomerization. Biochemistry 1998;37(43):15177-87
   PubMed Web of Science ®Google Scholar
• Kage KL, Richardson PL, Traphagen L, et al. A high throughput fluorescent assay for measuring the activity of fatty acid amide hydrolase. J Neurosci Methods 2007;161(1):47-54
   PubMed Web of Science ®Google Scholar
• Huang H, Nishi K, Tsai HJ, Hammock BD. Development of highly sensitive fluorescent assays for fatty acid amide hydrolase. Anal Biochem 2007;363(1):12-21
   PubMed Web of Science ®Google Scholar
• Bracey MH, Hanson MA, Masuda KR, et al. Structural adaptations in a membrane enzyme that terminates endocannabinoid signaling. Science 2002;298(5599):1793-6
   PubMed Web of Science ®Google Scholar
• Patricelli MP, Lovato MA, Cravatt BF. Chemical and mutagenic investigations of fatty acid amide hydrolase: evidence for a family of serine hydrolases with distinct catalytic properties. Biochemistry 1999;38(31):9804-12
   PubMed Web of Science ®Google Scholar
• Patricelli MP, Cravatt BF. Clarifying the catalytic roles of conserved residues in the amidase signature family. J Biol Chem 2000;275(25):19177-84
   PubMed Web of Science ®Google Scholar
• McKinney MK, Cravatt BF. Evidence for distinct roles in catalysis for residues of the serine-serine-lysine catalytic triad of fatty acid amide hydrolase. J Biol Chem 2003;278(39):37393-9
   PubMed Web of Science ®Google Scholar
• Patricelli MP, Cravatt BF. Fatty acid amide hydrolase competitively degrades bioactive amides and esters through a nonconventional catalytic mechanism. Biochemistry 1999;38(43):14125-30
   PubMed Web of Science ®Google Scholar
• Ahn K, Johnson DS, Fitzgerald LR, et al. Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity. Biochemistry 2007;46(45):13019-30
   PubMed Web of Science ®Google Scholar
• Koutek B, Prestwich GD, Howlett AC, et al. Inhibitors of arachidonoyl ethanolamide hydrolysis. J Biol Chem 1994;269(37):22937-40
   PubMed Web of Science ®Google Scholar
• Patterson JE, Ollman IR, Cravatt BF, et al. Inhibition of oleamide hydrolase catalyzed hydrolysis of the endogenous sleep-inducing lipid cis-9-octadecenamide. J Am Chem Soc 1996;118:5938-45
   Web of Science ®Google Scholar
• Boger DL, Sato H, Lerner AE, et al. Trifluoromethyl ketone inhibitors of fatty acid amide hydrolase: a probe of structural and conformational features contributing to inhibition. Bioorg Med Chem Lett 1999;9(2):265-70
   PubMed Web of Science ®Google Scholar
• Huang Z, Payette P, Abdullah K, et al. Functional identification of the active-site nucleophile of the human 85-kDa cytosolic phospholipase A2. Biochemistry 1996;35(12):3712-21
   PubMed Web of Science ®Google Scholar
• Deutsch DG, Omeir R, Arreaza G, et al. Methyl arachidonyl fluorophosphonate: a potent irreversible inhibitor of anandamide amidase. Biochem Pharmacol 1997;53(3):255-60
   PubMed Web of Science ®Google Scholar
• Hoover HS, Blankman JL, Niessen S, Cravatt BF. Selectivity of inhibitors of endocannabinoid biosynthesis evaluated by activity-based protein profiling. Bioorg Med Chem Lett 2008;18(22):5838-41
   PubMed Web of Science ®Google Scholar
• Leung D, Hardouin C, Boger DL, Cravatt BF. Discovering potent and selective reversible inhibitors of enzymes in complex proteomes. Nat Biotechnol 2003;21(6):687-91
   PubMed Web of Science ®Google Scholar
• Kidd D, Liu Y, Cravatt BF. Profiling serine hydrolase activities in complex proteomes. Biochemistry 2001;40(13):4005-15
   PubMed Web of Science ®Google Scholar
• Liu Y, Patricelli MP, Cravatt BF. Activity-based protein profiling: the serine hydrolases. Proc Natl Acad Sci USA 1999;96(26):14694-9
   PubMed Web of Science ®Google Scholar
• Patricelli MP, Giang DK, Stamp LM, Burbaum JJ. Direct visualization of serine hydrolase activities in complex proteomes using fluorescent active site-directed probes. Proteomics 2001;1(9):1067-71
   PubMed Web of Science ®Google Scholar
• Boger DL, Miyauchi H, Du W, et al. Discovery of a potent, selective, and efficacious class of reversible alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as analgesics. J Med Chem 2005;48(6):1849-56
   PubMed Web of Science ®Google Scholar
• Romero FA, Du W, Hwang I, et al. Potent and selective alpha-ketoheterocycle-based inhibitors of the anandamide and oleamide catabolizing enzyme, fatty acid amide hydrolase. J Med Chem 2007;50(5):1058-68
   PubMed Web of Science ®Google Scholar
• Leung D, Du W, Hardouin C, et al. Discovery of an exceptionally potent and selective class of fatty acid amide hydrolase inhibitors enlisting proteome-wide selectivity screening: concurrent optimization of enzyme inhibitor potency and selectivity. Bioorg Med Chem Lett 2005;15(5):1423-8
   PubMed Web of Science ®Google Scholar
• Garfunkle J, Ezzili C, Rayl TJ, et al. Optimization of the central heterocycle of alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase. J Med Chem 2008;51(15):4392-403
   PubMed Web of Science ®Google Scholar
• Romero FA, Hwang I, Boger DL. Delineation of a fundamental alpha-ketoheterocycle substituent effect for use in the design of enzyme inhibitors. J Am Chem Soc 2006;128(43):14004-5
   PubMed Web of Science ®Google Scholar
• Hardouin C, Kelso MJ, Romero FA, et al. Structure-activity relationships of alpha-ketooxazole inhibitors of fatty acid amide hydrolase. J Med Chem 2007;50(14):3359-68
   PubMed Web of Science ®Google Scholar
• Kimball FS, Romero FA, Ezzili C, et al. Optimization of alpha-ketooxazole inhibitors of fatty acid amide hydrolase. J Med Chem 2008;51(4):937-47
   PubMed Web of Science ®Google Scholar
• Timmons A, Seierstad M, Apodaca R, et al. Novel ketooxazole based inhibitors of fatty acid amide hydrolase (FAAH). Bioorg Med Chem Lett 2008;18(6):2109-13
   PubMed Web of Science ®Google Scholar
• Fegley D, Gaetani S, Duranti A, et al. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3′-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther 2005;313(1):352-8
   PubMed Web of Science ®Google Scholar
• Swinney DC. Biochemical mechanisms of drug action: what does it take for success? Nat Rev Drug Discov 2004;3(9):801-8
   PubMed Web of Science ®Google Scholar
• Tarzia G, Duranti A, Tontini A, et al. Design, synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors. J Med Chem 2003;46(12):2352-60
   PubMed Web of Science ®Google Scholar
• Mor M, Rivara S, Lodola A, et al. Cyclohexylcarbamic acid 3′- or 4′-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies. J Med Chem 2004;47(21):4998-5008
   PubMed Web of Science ®Google Scholar
• Piomelli D, Tarzia G, Duranti A, et al. Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS Drug Rev 2006 Spring;12(1):21-38
   PubMedGoogle Scholar
• Mor M, Lodola A, Rivara S, et al. Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl alkylcarbamates. J Med Chem 2008;51(12):3487-98
   PubMed Web of Science ®Google Scholar
• Alexander JP, Cravatt BF. Mechanism of carbamate inactivation of FAAH: implications for the design of covalent inhibitors and in vivo functional probes for enzymes. Chem Biol 2005;12(11):1179-87
   PubMed Web of Science ®Google Scholar
• Lodola A, Mor M, Rivara S, et al. Identification of productive inhibitor binding orientation in fatty acid amide hydrolase (FAAH) by QM/MM mechanistic modelling. Chem Commun (Camb) 2008;14(2):214-6
   Google Scholar
• AAbouabdellah A, Burnier P, Hoornaert C, et al. US20060089344;2006
   Google Scholar
• Abouabdellah A, Almario Garcia A, Hoornaert C, et al. WO2005090347;2005
   Google Scholar
• Zhang D, Saraf A, Kolasa T, et al. Fatty acid amide hydrolase inhibitors display broad selectivity and inhibit multiple carboxylesterases as off-targets. Neuropharmacology 2007;52(4):1095-105
   PubMed Web of Science ®Google Scholar
• Sit SY, Conway C, Bertekap R, et al. Novel inhibitors of fatty acid amide hydrolase. Bioorg Med Chem Lett 2007;17(12):3287-91
   PubMed Web of Science ®Google Scholar
• Ishii T, Sugane T, Maeda J, et al. WO2006088075;2006
   Google Scholar
• Matsumoto T, Kori M, Miyazaki J, et al. WO2006054652;2006
   Google Scholar
• Apodaca R, Breitenbucher JG, Pattabiraman K, et al. WO2006074025;2006
   Google Scholar
• Apodaca R, Breitenbucher JG, Pattabiraman K, et al. WO2007005510;2007
   Google Scholar
• Keith JM, Apodaca R, Xiao W, et al. Thiadiazolopiperazinyl ureas as inhibitors of fatty acid amide hydrolase. Bioorg Med Chem Lett 2008;18(17):4838-43
   PubMed Web of Science ®Google Scholar
• Fay LK, Johnson DS, Lazerwith SE, et al. WO2008047229;2008
   Google Scholar
• Ishii T, Sugane T, Kakefuda A, et al. WO2008023720;2008
   Google Scholar
• Copeland RA. Evaluation of enzyme inhibitors in drug discovery. A guide for medicinal chemists and pharmacologists. Methods Biochem Anal 2005;46:1-265
   PubMedGoogle Scholar
• Wei BQ, Mikkelsen TS, McKinney MK, et al. A second fatty acid amide hydrolase with variable distribution among placental mammals. J Biol Chem 2006;281(48):36569-78
   PubMed Web of Science ®Google Scholar
• Karbarz MJ, Luo L, Chang L, et al. Biochemical and biological properties of 4-(3-phenyl-[1,2,4] thiadiazol-5-yl)-piperazine-1-carboxylic acid phenylamide, a mechanism-based inhibitor of fatty acid amide hydrolase. Anesth Analg 2009;108(1):316-29
   PubMed Web of Science ®Google Scholar
• Apodaca R, Breitenbucher JG, Hawryluk NA, et al. WO2008153752;2008
   Google Scholar
• Moore SA, Nomikos GG, Dickason-Chesterfield AK, et al. Identification of a high-affinity binding site involved in the transport of endocannabinoids. Proc Natl Acad Sci USA 2005;102(49):17852-7
   PubMed Web of Science ®Google Scholar
• Alexander JP, Cravatt BF. The putative endocannabinoid transport blocker LY2183240 is a potent inhibitor of FAAH and several other brain serine hydrolases. J Am Chem Soc 2006;128(30):9699-704
   PubMed Web of Science ®Google Scholar
• Even L, Hoornaert C. WO2008145839;2008
   Google Scholar
• Adams J, Behnke ML, Castro AC, et al. WO2008063300;2008
   Google Scholar
• Minkkila A, Saario SM, Kasnanen H, et al. Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase. J Med Chem 2008;51(22):7057-60
   PubMed Web of Science ®Google Scholar
• Dembitsky VM, Quntar AA, Srebnik M. Recent advances in the medicinal chemistry of alpha-aminoboronic acids, amine-carboxyboranes and their derivatives. Mini Rev Med Chem 2004;4(9):1001-18
   PubMed Web of Science ®Google Scholar
• Bartolini W, Cali BM, Chen B, et al. WO2005002525;2005
   Google Scholar
• Wang X, Sarris K, Kage K, et al. Synthesis and evaluation of benzothiazole-based analogues as novel, potent, and selective fatty acid amide hydrolase inhibitors. J Med Chem 2009;52(1):170-80
   PubMed Web of Science ®Google Scholar
• Kelly MG, Kincaid J, Gowlugari S, WO2009011904;2009
   Google Scholar
• Farrell EK, Merkler DJ. Biosynthesis, degradation and pharmacological importance of the fatty acid amides. Drug Discov Today 2008;13(13-14):558-68
   PubMed Web of Science ®Google Scholar
• Bambico FR, Gobbi G. The cannabinoid CB1 receptor and the endocannabinoid anandamide: possible antidepressant targets. Expert Opin Ther Targets 2008;12(11):1347-66
   PubMed Web of Science ®Google Scholar
• Rock EM, Limebeer CL, Mechoulam R, et al. The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) elicited by a lithium-paired context in the rat. Psychopharmacology (Berl) 2008;196(3):389-95
   PubMed Web of Science ®Google Scholar
• Batkai S, Pacher P, Osei-Hyiaman D, et al. Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation 2004;110(14):1996-2002
   PubMed Web of Science ®Google Scholar
• Scherma M, Panlilio LV, Fadda P, et al. Inhibition of anandamide hydrolysis by cyclohexyl carbamic acid 3′-carbamoyl-3-yl ester (URB597) reverses abuse-related behavioral and neurochemical effects of nicotine in rats. J Pharmacol Exp Ther 2008;327(2):482-90
   PubMed Web of Science ®Google Scholar
• Kreitzer AC, Malenka RC. Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. Nature 2007;445(7128):643-7
   PubMed Web of Science ®Google Scholar
• Palmer JA, Higuera ES, Chang L, Chaplan SR. Fatty acid amide hydrolase inhibition enhances the anti-allodynic actions of endocannabinoids in a model of acute pain adapted for the mouse. Neuroscience 2008;154(4):1554-61
   PubMed Web of Science ®Google Scholar
• Schlosburg JE, Boger DL, Cravatt BF, Lichtman AH. Endocannabinoid modulation of scratching response in an acute allergenic model: a new prospective neural therapeutic target for pruritus. J Pharmacol Exp Ther 2009;329(1):314-23
   PubMed Web of Science ®Google Scholar
• Jayamanne A, Greenwood R, Mitchell VA, et al. Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br J Pharmacol 2006;147(3):281-8
   PubMed Web of Science ®Google Scholar
• Jhaveri MD, Richardson D, Kendall DA, et al. Analgesic effects of fatty acid amide hydrolase inhibition in a rat model of neuropathic pain. J Neurosci 2006;26(51):13318-27
   PubMed Web of Science ®Google Scholar
• Wise LE, Cannavacciulo R, Cravatt BF, et al. Evaluation of fatty acid amides in the carrageenan-induced paw edema model. Neuropharmacology 2008;54(1):181-8
   PubMed Web of Science ®Google Scholar
• Haller VL, Cichewicz DL, Welch SP. Non-cannabinoid CB1, non-cannabinoid CB2 antinociceptive effects of several novel compounds in the PPQ stretch test in mice. Eur J Pharmacol 2006;546(1-3):60-8
   PubMed Web of Science ®Google Scholar
• Naidu PS, Booker L, Cravatt BF, Lichtman AH. Synergy between enzyme inhibitors of fatty acid amide hydrolase and cyclooxygenase in visceral nociception. J Pharmacol Exp Ther 2009;329(1):48-56
   PubMed Web of Science ®Google Scholar
• Hohmann AG, Suplita RL, Bolton NM, et al. An endocannabinoid mechanism for stress-induced analgesia. Nature 2005;435(7045):1108-12
   PubMed Web of Science ®Google Scholar
• Storr MA, Keenan CM, Emmerdinger D, et al. Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors. J Mol Med 2008;86(8):925-36
   PubMed Web of Science ®Google Scholar
• Storr MA, Yuce B, Andrews CN, Sharkey KA. The role of the endocannabinoid system in the pathophysiology and treatment of irritable bowel syndrome. Neurogastroenterol Motil 2008;20(8):857-68
   PubMed Web of Science ®Google Scholar
• Patel S, Hillard CJ. Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. J Pharmacol Exp Ther 2006;318(1):304-11
   PubMed Web of Science ®Google Scholar
• Scherma M, Medalie J, Fratta W, et al. The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition. Neuropharmacology 2008;54(1):129-40
   PubMed Web of Science ®Google Scholar
• Bortolato M, Mangieri RA, Fu J, et al. Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biol Psychiatry 2007;62(10):1103-10
   PubMed Web of Science ®Google Scholar
• Haller J, Barna I, Barsvari B, et al. Interactions between environmental aversiveness and the anxiolytic effects of enhanced cannabinoid signaling by FAAH inhibition in rats. Psychopharmacology (Berl) 2009, in press
   PubMedGoogle Scholar
• Moise AM, Eisenstein SA, Astarita G, et al. An endocannabinoid signaling system modulates anxiety-like behavior in male Syrian hamsters. Psychopharmacology (Berl) 2008;200(3):333-46
   PubMed Web of Science ®Google Scholar
• Trezza V, Vanderschuren LJ. Cannabinoid and opioid modulation of social play behavior in adolescent rats: differential behavioral mechanisms. Eur Neuropsychopharmacol 2008;18(7):519-30
   PubMed Web of Science ®Google Scholar
• Trezza V, Vanderschuren LJ. Bidirectional cannabinoid modulation of social behavior in adolescent rats. Psychopharmacology (Berl) 2008;197(2):217-27
   PubMed Web of Science ®Google Scholar
• Lisboa SF, Resstel LB, Aguiar DC, Guimaraes FS. Activation of cannabinoid CB1 receptors in the dorsolateral periaqueductal gray induces anxiolytic effects in rats submitted to the Vogel conflict test. Eur J Pharmacol 2008;593(1-3):73-8
   PubMed Web of Science ®Google Scholar
• Batkai S, Mukhopadhyay P, Harvey-White J, et al. Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats. Am J Physiol Heart Circ Physiol 2007;293(3):H1689-95
   PubMed Web of Science ®Google Scholar
• Melis M, Pillolla G, Luchicchi A, et al. Endogenous fatty acid ethanolamides suppress nicotine-induced activation of mesolimbic dopamine neurons through nuclear receptors. J Neurosci 2008;28(51):13985-94
   PubMed Web of Science ®Google Scholar
• Nucci C, Gasperi V, Tartaglione R, et al. Involvement of the endocannabinoid system in retinal damage after high intraocular pressure-induced ischemia in rats. Invest Ophthalmol Vis Sci 2007;48(7):2997-3004
   PubMed Web of Science ®Google Scholar
• Long JZ, Li W, Booker L, et al. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol 2009;5(1):37-44
   PubMed Web of Science ®Google Scholar
• Jessani N, Cravatt BF. The development and application of methods for activity-based protein profiling. Curr Opin Chem Biol 2004;8(1):54-9
   PubMed Web of Science ®Google Scholar
• Speers AE, Cravatt BF. Chemical strategies for activity-based proteomics. Chembiochem 2004;5(1):41-7
   PubMed Web of Science ®Google Scholar
• Sipe JC, Chiang K, Gerber AL, et al. A missense mutation in human fatty acid amide hydrolase associated with problem drug use. Proc Natl Acad Sci USA 2002;99(12):8394-9
   PubMed Web of Science ®Google Scholar
• Tyndale RF, Payne JI, Gerber AL, Sipe JC. The fatty acid amide hydrolase C385A (P129T) missense variant in cannabis users: studies of drug use and dependence in Caucasians. Am J Med Genet B Neuropsychiatr Genet 2007;144(5):660-6
   Google Scholar
• Sipe JC, Waalen J, Gerber A, Beutler E. Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH). Int J Obes (Lond) 2005;29(7):755-9
   PubMed Web of Science ®Google Scholar
• Justinova Z, Mangieri RA, Bortolato M, et al. Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates. Biol Psychiatry 2008;64(11):930-7
   PubMed Web of Science ®Google Scholar
• Jensen DP, Andreasen CH, Andersen MK, et al. The functional Pro129Thr variant of the FAAH gene is not associated with various fat accumulation phenotypes in a population-based cohort of 5,801 whites. J Mol Med 2007;85(5):445-9
   PubMed Web of Science ®Google Scholar
• Vinod KY, Sanguino E, Yalamanchili R, et al. Manipulation of fatty acid amide hydrolase functional activity alters sensitivity and dependence to ethanol. J Neurochem 2008;104(1):233-43
   PubMed Web of Science ®Google Scholar
• Blednov YA, Cravatt BF, Boehm SL 2nd, et al. Role of endocannabinoids in alcohol consumption and intoxication: studies of mice lacking fatty acid amide hydrolase. Neuropsychopharmacology 2007;32(7):1570-82
   PubMed Web of Science ®Google Scholar
• Maccarrone M, Valensise H, Bari M, et al. Relation between decreased anandamide hydrolase concentrations in human lymphocytes and miscarriage. Lancet 2000;355(9212):1326-9
   PubMed Web of Science ®Google Scholar
• Maccarrone M, Bisogno T, Valensise H, et al. Low fatty acid amide hydrolase and high anandamide levels are associated with failure to achieve an ongoing pregnancy after IVF and embryo transfer. Mol Hum Reprod 2002;8(2):188-95
   PubMed Web of Science ®Google Scholar
• Wang H, Xie H, Guo Y, et al. Fatty acid amide hydrolase deficiency limits early pregnancy events. J Clin Invest 2006;116(8):2122-31
   PubMed Web of Science ®Google Scholar
• Sun X, Wang H, Okabe M, et al. Genetic loss of Faah compromises male fertility in mice. Biol Reprod 2009;80(2):235-42
   PubMed Web of Science ®Google Scholar
• Available from: www.clinicaltrials.gov
   Google Scholar